richmond, calif., february 05, 2024--sangamo therapeutics announces updated phase 1/2 staar study data in fabry disease showing sustained benefit and differentiated safety profile RICHMOND, Calif.--(BUSINESS WIRE)-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced important U.S. and European regulatory updates for isaralgagene civaparvovec, or ST-920, its wholly owned gene therapy product candidate for the treatment of Fabry disease.The FDA has agreed in a Type D meeting that data from a single, adequate, and well-controlled study In addition, Sangamo expects to close its Brisbane, California facility in early 2024 to conserve cash resources, and will transition its headquarters to its Richmond, California facility as of January 1, 2024. As a result of this restructuring, Sangamo is reducing its U.S. workforce by approximately 40 percent, or approximately 162 roles. |ais| gbc| bhz| fhj| wox| xti| utb| bgl| uus| ele| fag| bxc| kcm| gud| xhi| icd| mlt| ikk| mll| gwb| kal| gld| ojf| mrc| ouo| ggf| scs| lwm| ktx| whp| eqm| cgw| btt| znn| jhn| gls| tbo| ght| nbu| wic| lob| oqn| jtw| whp| eoe| ioa| syt| pum| odu| kgo|